US Court Denies Attempt To Silence Leaks In Pricing Litigation
Executive Summary
A host of leading generics firms have been denied a requested order to prevent leaks and potentially harmful public allegations as part of multi-district litigation over generics pricing in the US.
You may also be interested in...
Teva, Viatris, Sun Set To Face Sprawling US Derma Price-Fixing Suit
A US federal court told generics manufacturers that it considered “plausibility, not probability” when deciding if price-fixing claims can move forward, in a generic topical drugs suit that forms part of broader multidistrict antitrust litigation.
Third Price-Fixing Lawsuit Filed In US
A third major price-fixing lawsuit has been filed in the US, naming over two dozen companies and ten individuals in allegations covering 80 generic presentations, focusing in particular on topical drugs.
Further US Lawsuit Claims Price-Fixing Conspiracy
Teva, along with Mylan, Pfizer, Sandoz and 16 other generics manufacturers, have found themselves in the spotlight after a further multi-state US lawsuit has accused them of participating in a price-fixing conspiracy.